Semaglutide + Cagrilintide Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 68 weeks total (16-week titration + 52-week maintenance); no planned off-cycle break
• Frequency: Once weekly, same day each week; subcutaneous injection
• Common delivery routes: Subcutaneous (abdomen or outer thigh preferred)
• Key timing notes: Consistency on the same day each week matters more than the specific hour; dose escalation steps every four weeks, not sooner

Who This Protocol Is For

The semaglutide + cagrilintide combination, known clinically as CagriSema, is researched for significant, sustained weight loss in people who have not achieved their goals through diet and activity alone. The profile that appears repeatedly across clinical trial data is adults with a body mass index in the obesity range, or in the overweight range when other weight-related health concerns are present. This is not a short-term solution for modest fat loss. The 68-week structure signals upfront what kind of commitment the protocol involves.

People who research this combination seriously are often already familiar with semaglutide, or are already on it, and want to understand what adding an amylin analogue actually changes. The mechanism difference matters here: semaglutide works through the GLP-1 receptor to slow gastric emptying and reduce appetite, while cagrilintide targets amylin receptors to produce early satiety through a separate central pathway. The two mechanisms are additive rather than redundant, which is the clinical rationale for combining them.

Experience with GLP-1 agonists shapes how someone approaches this protocol significantly. Someone already stabilized on semaglutide has a different starting conversation than a first-time user. Community protocols for people adding cagrilintide to existing semaglutide use apply a different titration logic, where cagrilintide is introduced gradually while the semaglutide dose is held, rather than the synchronized escalation used in the REDEFINE Phase 3 trials.

Delivery preference is straightforward for this combination: subcutaneous injection is the route for both compounds. For people with needle aversion, that is a relevant reality to account for before committing to a once-weekly injection protocol that runs for over a year.

How Is a Semaglutide + Cagrilintide Cycle Structured?

The full protocol arc is 68 weeks. It has two distinct phases: a 16-week titration phase where both compounds are escalated in tandem, and a 52-week maintenance phase where both are held at the full dose. The REDEFINE Phase 3 trial design also included a 7-week observation window with no injections following the 68 weeks of active treatment, but that is a research follow-up structure, not a therapeutic off-cycle.

The titration phase is where the most active management happens. Both semaglutide and cagrilintide move up together through five steps, each lasting four weeks. Think of it like gradually turning up two dials at the same rate rather than pushing both to maximum at once. The purpose is tolerability: GI side effects are the dominant challenge with this combination, and the stepped escalation gives the body time to adapt at each level before the next increase. Rushing this phase is the most common reason people abandon the protocol before reaching the maintenance stage.

The maintenance phase is structurally simpler. Once both compounds reach the full dose, the protocol settles into a steady weekly rhythm and holds there. Trial data from the REDEFINE 1 Phase 3 study showed continued weight loss through the full 52-week maintenance window rather than a rapid early drop followed by a plateau. Mean weight reduction across 68 weeks reached approximately 20 to 23 percent of baseline body weight, with nearly 92 percent of participants achieving at least 5 percent weight loss.

Unlike most compounds in the peptide space, this combination does not have a designed off-cycle. It is built to run continuously. What cycling means in this context is addressed in the Off-Cycle Considerations section.

How Your Dose Is Determined

What moves a semaglutide + cagrilintide dose:

• Your goal: This combination is researched specifically for sustained weight loss rather than mild metabolic maintenance. The titration schedule escalates toward a target maintenance dose, and reaching that target is the clinical benchmark. People with more significant weight loss goals or greater metabolic burden trend toward reaching and holding the full dose, while some protocols for people earlier in their weight management journey find meaningful benefit at intermediate steps without pushing all the way to the maximum.
• Experience level: Someone already stabilized on semaglutide approaches titration differently than a first-time user. When cagrilintide is added to an existing semaglutide protocol, the semaglutide dose is typically held steady while cagrilintide is introduced and escalated on its own stepped schedule, rather than the synchronized approach used in the REDEFINE trials.
• Delivery format: The fixed-dose combination delivers both compounds in one injection from a dual-chamber device, meaning both drugs move up in lockstep. When the two are used separately, there is more flexibility to adjust one while holding the other, which some protocols use to manage tolerability. This format choice influences how the dose is structured across the titration.
• Individual response: GI tolerability is the primary driver of dose variability in practice. In the REDEFINE 1 trial, about 75 percent of participants reached the full target dose at some point, but only about 57 percent maintained it through week 68. The rest required dose reductions or pauses due to side effects. Where someone lands on the range depends heavily on how their GI system adapts across the titration steps.

The dose interacts with tolerability in a way that makes the escalation schedule functionally inseparable from the dose itself. A dose that someone cannot sustain produces no maintenance-phase results. That balance between the goal dose and the tolerable dose is exactly what a personalized protocol accounts for, and there is no single number that fits everyone regardless of starting point or GI response.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your weight loss goal, your prior experience with GLP-1 agonists, and your GI tolerability history and builds your semaglutide + cagrilintide protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take Semaglutide + Cagrilintide?

Both compounds are administered once per week, every seven days, as a single subcutaneous injection. The once-weekly frequency is not arbitrary. Cagrilintide is a long-acting amylin analogue engineered specifically for weekly dosing, with a pharmacokinetic profile that sustains stable plasma levels across a seven-day window. Semaglutide carries the same design logic, with a half-life of approximately one week. Dosing more frequently would not increase efficacy and would introduce dose-stacking risk.

The practical timing rule is consistency on the same day each week rather than the same hour. Most protocols do not require a specific clock time, but choosing a fixed day and maintaining it reduces accidental drift, missed windows, and the coverage gaps that come with irregular spacing. Many people anchor the injection to an existing weekly routine to make adherence automatic rather than something to actively remember.

Injection site rotation is a genuine consideration. The abdomen and outer thigh are the preferred subcutaneous sites. Rotating within and between those sites week to week reduces local tissue reactions, which are more prominent with this combination than with semaglutide alone, particularly at higher maintenance doses.

If a weekly dose is missed, the correct response is to resume on the next scheduled day without doubling up. A doubled dose does not recover the missed therapeutic window and substantially increases GI side effect risk.

Loading and Maintenance Phases

The titration phase is the loading phase, and understanding what it is actually doing changes how people manage it. It is not a lower-dose warm-up that gets replaced by something fundamentally different. It is a stepwise escalation that adapts the body to each dose level before moving to the next, with the therapeutic load building progressively toward the full maintenance dose. The dose stays consistent within each four-week block; what changes across the titration is the dose level, not the nature of the intervention.

In the synchronized fixed-combination protocol from the REDEFINE trials, both semaglutide and cagrilintide start at the same low dose and escalate together through five steps, spending four weeks at each level before increasing. Nausea tends to peak during escalation into the middle dose steps, roughly weeks five through eight for most people. The four-week hold at each step gives the body adaptation time before the next increase. Compressing the schedule because early steps felt manageable is one of the most reliable ways to arrive at intolerable side effects at a higher step.

The maintenance phase begins once both compounds reach the target dose, typically around week seventeen on the synchronized escalation schedule. At that point the protocol stabilizes: same dose, same day each week, held for the remainder of the protocol. Trial data showed continued progressive weight loss throughout the 52-week maintenance window, not an early spike followed by a plateau.

For people adding cagrilintide to an already-established semaglutide dose, the loading-phase logic applies to the cagrilintide component only. Semaglutide is held at its current level, and cagrilintide is introduced at a lower starting point and escalated independently until it reaches its target. If side effects become intolerable at any step, dropping back to the previous dose level for two to four weeks before retrying is the appropriate move, not stopping the protocol entirely.

Off-Cycle Considerations

The honest answer is that this protocol does not have a designed off-cycle. Clinical trial data ran participants for 68 weeks of active treatment with no planned break. The rationale mirrors the model for semaglutide alone: appetite regulation through GLP-1 agonism and amylin receptor signaling is a continuous intervention, not a short course that concludes and leaves a new baseline in place.

The 7-week post-treatment window at the end of the REDEFINE trials was an observation period for research purposes, not a therapeutic off-cycle. The data from that window is instructive: weight loss effects attenuate when the compounds are stopped, consistent with what is observed with semaglutide monotherapy. The appetite regulatory benefit depends on the compounds being present.

The language of cycling on and off comes from the broader peptide space, where shorter courses with rest periods are common. That framework does not map cleanly onto this combination. When people use cycle language in the context of CagriSema, they typically mean taking a break due to side effect management, cost, or access constraints, or transitioning to a reduced maintenance approach after significant weight loss. Those are practical decisions rather than built-in protocol design, and they belong in a clinical conversation rather than a structured protocol template. When breaks are taken for tolerability or access reasons, stepping the dose down before stopping is generally preferred over abrupt discontinuation.

The current evidence supports continuous use for sustained benefit.

What to Expect Week by Week

• Week 1 to 4: The starting dose is intentionally low. Many people report minimal effects in the first week, with appetite changes becoming faintly noticeable for some within a few days of the first injection. Nausea is possible but usually mild at this step. Weight loss progress in this window is typically modest.
• Week 5 to 8: The first dose escalation is where the protocol begins to feel real for most people. Appetite suppression becomes more pronounced, and this is also when nausea peaks for the majority of users. Community accounts consistently describe this window as the most challenging GI phase. For people who work through it, the adaptation that follows brings a meaningful shift in hunger signaling.
• Week 9 to 12: The mid-escalation range brings stronger, more consistent appetite suppression. People commonly report that thoughts about food decrease noticeably, that meals become significantly smaller without feeling deprived, and that weight loss is now clearly progressive. The difference in weight loss versus semaglutide alone becomes statistically apparent in trial data during this window.
• Week 13 to 16: The final titration step brings both compounds to the full maintenance dose. This is the peak GI burden window, and also when maximum appetite suppression arrives. Approximately 75 percent of participants in the REDEFINE 1 trial reached this dose at some point during the protocol.
• Week 17 and beyond: The maintenance phase is where the bulk of cumulative weight loss accumulates. Mean weight reduction across 68 weeks reached approximately 20 to 23 percent of baseline body weight, with nearly 92 percent of participants achieving at least 5 percent loss.

These are commonly reported ranges drawn from Phase 3 clinical trial data and real-world community protocols, not a promise or prediction for any individual. What a well-run cycle looks like when it goes right: the most pronounced shift in appetite signaling arrives in the mid-escalation phase, and the bulk of the weight loss accumulates through the long maintenance window. People who tolerate the titration without shortcutting the schedule and stay consistent on the weekly cadence commonly report that the hunger changes feel qualitatively different from other appetite interventions, with food simply becoming less mentally prominent rather than requiring constant willpower. Individual results vary by adherence, tolerability, and personal metabolic response.

Common Protocol Mistakes

Rushing the titration schedule. The four-week hold at each dose step is functional, not arbitrary. Escalating faster because early steps feel manageable is the most common way to arrive at a dose level that produces intolerable nausea or GI distress. The adaptation that the slower schedule builds is the reason the full maintenance dose is achievable at all.

Skipping or irregularly spacing weekly doses. Missing an injection and doubling the next one does not recover the lost therapeutic window. It substantially increases GI risk and disrupts the stable plasma levels the weekly half-life depends on. The correct response to a missed dose is to resume on the next scheduled day at the usual amount.

Starting both drugs at full dose simultaneously. For people already on semaglutide who are adding cagrilintide, beginning cagrilintide at the maintenance target dose without titrating is a reliable way to produce severe GI side effects. Trial data showed GI adverse events in approximately 80 percent of participants even under a controlled stepped escalation. Starting at the full dose amplifies that risk substantially. The add-on approach introduces cagrilintide at a lower starting dose and escalates it independently while semaglutide is held.

Pushing through intolerable side effects without adjusting dose. Some nausea during escalation is expected and manageable. Severe, persistent GI symptoms without dose adjustment are neither necessary nor productive. The right protocol move is to step back to the previous dose level for two to four weeks before attempting the increase again. Stepping back is not a failure; it is the correct protocol response.

Measurement errors with compounded versions. The FDA has documented cases where patients drew up significantly more of a compounded semaglutide preparation than intended due to confusion between milligrams, milliliters, and syringe unit markings, with some errors producing overdoses requiring emergency care. If a compounded format is being used, precision in measurement and using the correct syringe type for the concentration are non-negotiable.

Stopping the protocol during the escalation phase. The weight loss trajectory for this combination is long and not front-loaded. People who stop in the mid-escalation phase because early progress feels slow are stopping before the maintenance-phase accumulation occurs. Trial data showed continued weight loss through the end of the 52-week maintenance window.

As of this writing, CagriSema has not received FDA approval for human use and remains investigational. Any use outside a supervised clinical trial or directly supervised medical context is considered unapproved.

Frequently Asked Questions

How long is a typical semaglutide + cagrilintide cycle?

The clinical protocol runs 68 weeks: a 16-week titration phase followed by 52 weeks of maintenance dosing. This is considerably longer than most peptide protocols in the research and biohacking space. There is no designed off-cycle break; the combination is built for continuous long-term use, and the appropriate duration for any individual depends on their goals, response, and ongoing clinical guidance.

How often do you take semaglutide + cagrilintide?

Both compounds are taken once per week, every seven days, as a single subcutaneous injection. This frequency is built into how both drugs behave in the body: cagrilintide is engineered as a long-acting amylin analogue and semaglutide has an approximately one-week half-life. Choosing a consistent day each week and maintaining it matters more than the specific time of day.

Does semaglutide + cagrilintide need a loading phase?

Yes, in a meaningful sense. The 16-week titration phase functions as the loading phase, escalating both compounds through five dose steps over four weeks each. This stepped escalation exists primarily to manage GI tolerability as the dose increases. Compressing or skipping steps is the most common cause of intolerable side effects and early dropout from the protocol.

Do you need to cycle off semaglutide + cagrilintide?

There is no designed off-cycle in the clinical protocol. The combination is intended for continuous use, and trial data showed that weight loss benefits attenuate when treatment stops, consistent with the mechanism of ongoing appetite regulation. Decisions about reducing or pausing the protocol after reaching a goal are clinical conversations rather than built-in protocol design.

What is CagriSema and how is it different from semaglutide alone?

CagriSema is the clinical name for the fixed-dose combination of cagrilintide and semaglutide. Semaglutide works through the GLP-1 receptor to slow gastric emptying and reduce appetite; cagrilintide adds amylin receptor agonism, producing early satiety through a separate central pathway. Because the two mechanisms are additive rather than redundant, the combination produces greater weight loss in trial data than either compound alone, with the REDEFINE 1 Phase 3 trial showing mean weight reduction in the range of 20 to 23 percent of baseline body weight across 68 weeks.

Can semaglutide and cagrilintide be used separately rather than as a fixed combination?

Some protocols use the two compounds independently rather than as a fixed-dose combination. This allows more flexibility in adjusting each drug's dose separately, which is particularly relevant when adding cagrilintide to an existing semaglutide protocol. In that case, cagrilintide is introduced and titrated on its own stepped schedule while semaglutide is held at its current dose. The fixed-combination format synchronizes both compounds, which simplifies administration but offers less individual adjustment flexibility.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and real-world protocols for semaglutide + cagrilintide in one place.